Calliditas Therapeutics is engaged in the development and commercial of its FDA-approved product, Nefecon (marketed in United States under the name TARPEYO), for patients with the autoimmune renal disease immunoglobulin A, or IgA, nephropathy, and a portfolio of product candidates. The CALT average annual return since 2020 is shown above.
The Average Annual Return on the CALT average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CALT average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CALT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|